| Literature DB >> 33584994 |
Vinicius Rocha-Santos1, Daniel Reis Waisberg2, Rafael Soares Pinheiro2, Lucas Souto Nacif2, Rubens Macedo Arantes2, Liliana Ducatti2, Rodrigo Bronze Martino2, Luciana Bertocco Haddad2, Flavio Henrique Galvao2, Wellington Andraus2, Luiz Augusto Carneiro-D'Alburquerque2.
Abstract
BACKGROUND: Budd-Chiari syndrome (BCS) is a challenging indication for liver transplantation (LT) due to a combination of massive liver, increased bleeding, retroperitoneal fibrosis and frequently presents with stenosis of the inferior vena cava (IVC). Occasionally, it may be totally thrombosed, increasing the complexity of the procedure, as it should also be resected. The challenge is even greater when performing living-donor LT as the graft does not contain the retrohepatic IVC; thus, it may be necessary to reconstruct it. CASEEntities:
Keywords: Budd-Chiari syndrome; Case report; Hepatic veno-occlusive disease; Inferior vena cava; Liver transplantation; Living donors
Year: 2021 PMID: 33584994 PMCID: PMC7856862 DOI: 10.4254/wjh.v13.i1.151
Source DB: PubMed Journal: World J Hepatol
Figure 1Massive blood return by subcutaneous veins in the anterior abdominal wall, which required the use of venovenous bypass prior to the abdominal incision.
Laboratory tests results and normal range
|
|
|
|
| Hemoglobin | 12.6 g/dL | 12.5-17.5 g/dL |
| Leukocytes | 3.5 × 109/L | 4-11 × 109/L |
| Platelets | 80 × 103/mm3 | 150-400 × 103/mm3 |
| Total bilirubin | 1.73 mg/dL | 0.2-1 mg/dL |
| Direct bilirubin | 0.85 mg/dL | < 0.3 mg/dL |
| Alanine aminotransferase | 20 U/L | < 41 U/L |
| Aspartate aminotransferase | 35 U/L | < 37 U/L |
| Alkaline phosphatase | 78 U/L | 40-129 U/L |
| Gamma-glutamyl-transferase | 115 U/L | 8-91 U/L |
| Creatinine | 0.79 mg/dL | 0.7-1.2 mg/dL |
| Blood urea nitrogen | 31 mg/dL | 10-50 mg/dL |
| Sodium | 143 mEq/L | 135-145 mEq/L |
| Potassium | 3.9 mEq/L | 3.5-4.5 mEq/L |
| Albumin | 4.4 g/dL | 3.4-4.8 g/dL |
| Prothrombin time | 21.8 s | 9.4-12.5 s |
| International normalized ratio | 1.75 | 0.95-1.2 |
Figure 2Abdominal computed tomography scans, with a 3-year interval. A: Heterogeneously vascularized nodule in segment V, of 2 cm, more visible in delayed phase due to hypocaptation (arrow); B: Same nodule in segment V in an exam scan performed 3 years later, with 4 cm (arrow). Massive subcutaneous veins in the abdominal wall are noted (arrowhead); C: The retrohepatic vena cava is completely thrombosed, up to almost the right atrium (asterisk).
Figure 3Liver magnetic resonance imaging with hepatobiliary contrast (arterial phase). A: Hypervascularized nodule in segment V of 4 cm (arrow); B: Hypervascularized nodule in segment II of 2.3 cm (arrow).
Figure 4Intraoperative images. A: Reconstructed retrohepatic vena cava using an infrahepatic vena cava graft of a deceased donor; B: Revascularized graft showing the venous conduit anastomosed to the newly formed vena cava (asterisk) and the portal vein anastomosis (arrowhead); C: Graft final aspect after arterialization at the end of transplantation.
Figure 5Late postoperative abdominal computed tomography scan, portal phase. A: Graft with adequate aspect and preserved portal inflow (arrowhead); B: Coronal view showing patent retrohepatic vena cava (arrowhead) and preserved graft outflow; C: Sagittal view of patent retrohepatic vena cava (arrowhead).
Summary of all reported cases of living-donor liver transplantation for Budd-Chiari syndrome with inferior vena cava resection
|
|
|
|
|
|
| Yan |
| IVC replacement with cadaveric IVC allograft | Yes | Alive after 3 mo |
| Yamada |
| IVC resection without replacement | No | Alive after 10 mo |
| Shimoda |
| IVC replacement with autologous internal jugular vein, external iliac vein and suprarenal IVC | No | Alive after 17 mo |
| Sasaki |
| IVC replacement with cadaveric IVC allograft | No | N/A |
| Kazimi |
| IVC resection without replacement | No | Alive after 3 mo |
| Choi |
| IVC replacement with cadaveric IVC allograft ( | No | Both alive after a median follow-up of 18 mo |
| Ogura |
| IVC replacement with an inverted composite graft (Gore-Tex stretch vascular graft and transposed IVC) | Yes | Alive after 24 mo |
| Sakçak |
| IVC replacement with cadaveric aortic allografts | No | Alive after 4 mo |
| Fukuda |
| IVC resection without replacement | No | Alive after 60 mo |
| Yagci |
| IVC replacement with cadaveric IVC ( | No | 2 patients died due to biliary complications after 5 mo of follow-up |
| Cetinkunar |
| IVC replacement by cadaveric aortic allograft | No | Alive after 4 mo |
| Ara |
| IVC replacement with cadaveric IVC ( | No | 2 patients died due to recent HAT after LT, and 2 patients died of sepsis during follow-up |
| Pahari |
| IVC replacement with e-PTFE graft | No | Both alive after a median follow-up of 18 mo |
| Karaca |
| IVC resection without replacement | No | N/A |
| Sabra |
| IVC resection without replacement | No | Alive after 3 mo |
| Yagi |
| IVC replacement with an inverted composite graft (e-PTFE graft and transposed IVC) | Yes | Alive after 36 mo |
| Ionescu |
| IVC replacement with caval-dacron composite graft | No | Both alive (follow-up not available) |
| Yoon |
| IVC replacement with synthetic material (ringed polyester) | Yes ( | All alive after a median follow-up of 10.5 years |
| Gonultas |
| IVC replacement with cadaveric IVC allograft ( | No | All alive after median follow-up of 15 mo |
| Present study |
| IVC replacement with cadaveric IVC allograft | Yes | Alive after 25 mo |
N/A: Not available; e-PTFE: Polytetrafluoroethylene; HAT: Hepatic artery thrombosis; IVC: Inferior vena cava; RHV: Right hepatic vein; LT: Liver transplantation.